Prostate Stem Cell Antigen: A Jekyll and Hyde Molecule?

Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)-anchored cell surface protein. Although PSCA is thought to be involved in intracellular signaling, much remains unknown about its physiological function and regulatory mechanism in normal and cancer cells. It is up-regulated in several major cancers including prostate, bladder, and pancreatic cancers. The expression of PSCA is positively correlated with advanced clinical stage and metastasis in prostate cancers and is also associated with malignant progression of premalignant prostate lesions. Therefore, PSCA has been proposed as a biomarker of diagnosis and prognosis, as well as a target of therapy for these cancers. In addition, PSCA has also shown clinical potential in immunotherapy as a prostate-specific antigen, which, when presented by dendritic cells, may elicit strong tumor-specific immunity. In contrast, PSCA is down-regulated in esophageal and gastric cancer and may have a tumor-suppressing function in the gastric epithelium. Recent exciting findings that genetic variations of PSCA conferred increased risks of gastric cancer and bladder cancer have opened up a new avenue of research about the pathological function of PSCA. PSCA seems to be a Jekyll and Hyde molecule that plays differential roles, tumor promoting or suppressing, depending on the cellular context. Clin Cancer Res; 16(14); 3533–8. ©2010 AACR.

[1]  Hongbing Shen,et al.  Genetic variation of PSCA gene is associated with the risk of both diffuse‐ and intestinal‐type gastric cancer in a Chinese population , 2010, International journal of cancer.

[2]  L. Matera.  The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. , 2010, Cancer treatment reviews.

[3]  Shizhi Wang,et al.  Genetic variation in PSCA and bladder cancer susceptibility in a Chinese population. , 2010, Carcinogenesis.

[4]  W. Park,et al.  Prostate stem cell antigen mRNA in peripheral blood as a potential predictor of biochemical recurrence in high‐risk prostate cancer , 2010, Journal of surgical oncology.

[5]  D. Kufe,et al.  Mucins in cancer: function, prognosis and therapy , 2009, Nature Reviews Cancer.

[6]  A. Tekinay,et al.  Prostate Stem Cell Antigen Is an Endogenous lynx1-Like Prototoxin That Antagonizes α7-Containing Nicotinic Receptors and Prevents Programmed Cell Death of Parasympathetic Neurons , 2009, The Journal of Neuroscience.

[7]  Zhigang Zhao,et al.  Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia , 2009, The Prostate.

[8]  Jian Gu,et al.  Genetic variation in the prostate stem cell antigen gene PSCA confers susceptibility to urinary bladder cancer , 2009, Nature Genetics.

[9]  H. Ananias,et al.  Expression of the gastrin‐releasing peptide receptor, the prostate stem cell antigen and the prostate‐specific membrane antigen in lymph node and bone metastases of prostate cancer , 2009, The Prostate.

[10]  K. Tsuchida,et al.  Activin signaling as an emerging target for therapeutic interventions , 2009, Cell Communication and Signaling.

[11]  P. Sweeney,et al.  Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  Hartwig Huland,et al.  Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. , 2009, Clinical chemistry.

[13]  Hong Ding,et al.  Imaging pancreatic cancer using bioconjugated InP quantum dots. , 2009, ACS nano.

[14]  A. Wu,et al.  Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. , 2008, Protein engineering, design & selection : PEDS.

[15]  L. Penn,et al.  Reflecting on 25 years with MYC , 2008, Nature Reviews Cancer.

[16]  A. Wu,et al.  Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen–Expressing Tumors , 2008, Clinical Cancer Research.

[17]  Gavin Kelly,et al.  Genes Involved in Differentiation, Stem Cell Renewal, and Tumorigenesis Are Modulated in Telomerase-Immortalized Human Urothelial Cells , 2008, Molecular Cancer Research.

[18]  Yusuke Nakamura,et al.  Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer , 2008, Nature Genetics.

[19]  Zhao Zhigang,et al.  Flutamide reduced prostate cancer development and prostate stem cell antigen mRNA expression in high grade prostatic intraepithelial neoplasia , 2008, International journal of cancer.

[20]  M. L. Moore,et al.  Deletion of PSCA increases metastasis of TRAMP‐Induced prostate tumors without altering primary tumor formation , 2008, The Prostate.

[21]  Zhao Zhigang,et al.  The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate , 2008, The Prostate.

[22]  Andrew N. Gray,et al.  Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. , 2008, Cancer research.

[23]  M. K. Siu,et al.  Overexpression of prostate stem cell antigen is associated with gestational trophoblastic neoplasia , 2007, Histopathology.

[24]  Zhao Zhigang,et al.  Prostate stem cell antigen (PSCA) mRNA expression in prostatic intraepithelial neoplasia: implications for the development of prostate cancer , 2007, The Prostate.

[25]  L. Fu,et al.  Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen‐specific CD8+ T‐cell response and inhibits the PSCA+ tumors growth in mice , 2007, The journal of gene medicine.

[26]  E. Rieber,et al.  Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T‐cells , 2007, The Prostate.

[27]  T. Sasada,et al.  Increased levels of IgG antibodies against peptides of the prostate stem cell antigen in the plasma of pancreatic cancer patients. , 2007, Oncology reports.

[28]  M. Minden,et al.  A tumor suppressor and oncogene: the WT1 story , 2007, Leukemia.

[29]  S. Morrison,et al.  Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody , 2007, Journal of immunotherapy.

[30]  Zhao Zhigang,et al.  External beam radiotherapy (EBRT) suppressed prostate stem cell antigen (PSCA) mRNA expression in clinically localized prostate cancer , 2007, The Prostate.

[31]  Martin G Pomper,et al.  Radiolabeled Anti-Claudin 4 and Anti-Prostate Stem Cell Antigen: Initial Imaging in Experimental Models of Pancreatic Cancer , 2007, Molecular imaging.

[32]  W. Schultze‐Seemann,et al.  Vaccination of advanced prostate cancer patients with PSCA and PSA peptide‐loaded dendritic cells induces DTH responses that correlate with superior overall survival , 2006, International journal of cancer.

[33]  K. Toida,et al.  The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase‐polymerase chain reaction analysis , 2006, BJU international.

[34]  K. Toida,et al.  Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder , 2006, BJU international.

[35]  B. Ludewig,et al.  Dendritic cell-based multi-epitope immunotherapy of hormone-refractory prostate carcinoma , 2006, Cancer Immunology, Immunotherapy.

[36]  Zhao Zhigang,et al.  Complete androgen ablation suppresses prostate stem cell antigen (PSCA) mRNA expression in human prostate carcinoma , 2005, The Prostate.

[37]  Zhennan Gu,et al.  Anti-prostate stem cell antigen monoclonal antibody 1G8 induces cell death in vitro and inhibits tumor growth in vivo via a Fc-independent mechanism. , 2005, Cancer research.

[38]  H. Friess,et al.  Prostate Stem Cell Antigen Is a Putative Target for Immunotherapy in Pancreatic Cancer , 2005, Pancreas.

[39]  S. Horvath,et al.  Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases , 2005, Clinical Cancer Research.

[40]  D. Cao,et al.  Expression of Mesothelin, Fascin, and Prostate Stem Cell Antigen in Primary Ovarian Mucinous Tumors and Their Utility in Differentiating Primary Ovarian Mucinous Tumors From Metastatic Pancreatic Mucinous Carcinomas in the Ovary , 2005, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[41]  Juswinder Singh,et al.  A classification of disulfide patterns and its relationship to protein structure and function , 2004, Protein science : a publication of the Protein Society.

[42]  A. Bamezai.  Mouse Ly-6 proteins and their extended family: markers of cell differentiation and regulators of cell signaling. , 2004, Archivum immunologiae et therapiae experimentalis.

[43]  Zhao Zhigang,et al.  Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer , 2004, World journal of surgical oncology.

[44]  S. Horvath,et al.  Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer. , 2004, The Journal of urology.

[45]  K. Raj,et al.  The role of Notch in tumorigenesis: oncogene or tumour suppressor? , 2003, Nature Reviews Cancer.

[46]  D. Faigel,et al.  Novel Markers of Pancreatic Adenocarcinoma in Fine-Needle Aspiration: Mesothelin and Prostate Stem Cell Antigen Labeling Increases Accuracy in Cytologically Borderline Cases , 2003, Applied immunohistochemistry & molecular morphology : AIMM.

[47]  J. Rao,et al.  Immunocytochemical analysis of prostate stem cell antigen as adjunct marker for detection of urothelial transitional cell carcinoma in voided urine specimens. , 2003, The Journal of urology.

[48]  H. Friess,et al.  Detection of circulating tumor cells by cytokeratin 20 and prostate stem cell antigen RT-PCR in blood of patients with gastrointestinal cancers. , 2003, Anticancer research.

[49]  G. Snow,et al.  Characterization of the human Ly‐6 antigens, the newly annotated member Ly‐6K included, as molecular markers for head‐and‐neck squamous cell carcinoma , 2003, International journal of cancer.

[50]  R. Reiter,et al.  Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. , 2002, Molecular cancer research : MCR.

[51]  I. Vivanco,et al.  Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. , 2002, Molecular endocrinology.

[52]  V. Bilim,et al.  Reverse transcription-polymerase chain reaction detection of prostate-specific antigen, prostate-specific membrane antigen, and prostate stem cell antigen in one milliliter of peripheral blood: value for the staging of prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  O. Witte,et al.  Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  S. Mayor,et al.  The GPI-anchor and protein sorting , 2001, Cellular and Molecular Life Sciences CMLS.

[55]  G. Jakse,et al.  PSCA expression is regulated by phorbol ester and cell adhesion in the bladder carcinoma cell line RT112. , 2001, Cancer letters.

[56]  Zhennan Gu,et al.  Prostate stem cell antigen is overexpressed in human transitional cell carcinoma. , 2001, Cancer research.

[57]  J. Cameron,et al.  Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. , 2001, Cancer research.

[58]  R. Hubert,et al.  Anti-PSCA mAbs inhibit tumor growth and metastasis formation and prolong the survival of mice bearing human prostate cancer xenografts , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[59]  G. Jakse,et al.  Reduced expression of PSCA, a member of the LY-6 family of cell surface antigens, in bladder, esophagus, and stomach tumors. , 2000, Biochemical and biophysical research communications.

[60]  M. Loda,et al.  Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer , 2000, Oncogene.

[61]  M. Loda,et al.  Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer , 2000, Genes, chromosomes & cancer.

[62]  M. Loda,et al.  Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[63]  T. Guthrie,et al.  Prostate cancer. , 2020, American family physician.

[64]  T. Rephann,et al.  Association , 1973, ACM SIGSPATIAL International Workshop on Advances in Geographic Information Systems.

[65]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.